In 2024, a comprehensive study was published on the discovery of new inhibitors targeting S. aureus FabI as potential treatments for MRSA infections. The racemic mixture 5 in Figure was identified through high-throughput screening, demonstrating a favorable safety profile in murine models of MRSA-induced skin infections. Subsequent chiral resolution of 5 revealed that the (S)-enantiomer displayed potent antimicrobial activity, with MIC values ranging from 0.25 to 1 μg/mL and an IC50 for FabI of 0.094 μM, whereas the (R)-enantiomer was inactive against MRSA strains. Notably, the (S)-enantiomer consistently reduced the size of skin lesions in infected mice .